NAFL
MCID: NNL005
MIFTS: 61

Non-Alcoholic Fatty Liver Disease (NAFL)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Non-Alcoholic Fatty Liver Disease

MalaCards integrated aliases for Non-Alcoholic Fatty Liver Disease:

Name: Non-Alcoholic Fatty Liver Disease 12 25 15 17
Nonalcoholic Fatty Liver Disease 25 36 15
Non-Alcoholic Fatty Liver 12 15 17
Fatty Liver 25 54
Steatosis 25 17
Nafld 12 25
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 25
Nonalcoholic Steatohepatitis 25
Nafl 12
Nash 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208 DOID:0080546
KEGG 36 H01333

Summaries for Non-Alcoholic Fatty Liver Disease

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding. NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer). NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

MalaCards based summary : Non-Alcoholic Fatty Liver Disease, also known as nonalcoholic fatty liver disease, is related to non-alcoholic steatohepatitis and lipid metabolism disorder. An important gene associated with Non-Alcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Losartan and Milk thistle have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is not caused by heavy alcohol use.

KEGG : 36 It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Related Diseases for Non-Alcoholic Fatty Liver Disease

Diseases related to Non-Alcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 889, show less)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic steatohepatitis 34.3 MIR34A MIR21 MIR122
2 lipid metabolism disorder 32.2 MIR33A MIR21 MIR122
3 psoriasis 31.4 MIR31 MIR22 MIR21 MIR200A MIR122
4 body mass index quantitative trait locus 11 31.3 MIR378A MIR34A MIR27B MIR27A MIR22 MIR21
5 overnutrition 31.1 MIR378A MIR34A MIR27B MIR27A MIR22 MIR21
6 arteries, anomalies of 31.1 MIR34A MIR33A MIR29C MIR27B MIR27A MIR22
7 inherited metabolic disorder 30.8 MIR34A MIR21 MIR122
8 hepatocellular carcinoma 30.8 MIR34A MIR33A MIR31 MIR29C MIR27A MIR26A1
9 renal fibrosis 30.7 MIR29C MIR21 MIR200B
10 acquired metabolic disease 30.6 MIR378A MIR27B MIR27A MIR22 MIR21 MIR200A
11 lipid storage disease 30.6 MIR22 MIR21 MIR122
12 glucose metabolism disease 30.3 MIR378A MIR27A MIR22 MIR21 MIR140
13 bile duct adenocarcinoma 30.3 MIR31 MIR21 MIR140
14 muscular dystrophy, duchenne type 30.3 MIR34A MIR29C MIR22 MIR21
15 intestinal disease 30.2 MIR378A MIR34A MIR31 MIR29C MIR27B MIR22
16 lymphoma, hodgkin, classic 30.2 MIR21 MIR200A MIR140
17 pancreatic cancer 30.2 MIR34A MIR31 MIR27A MIR21 MIR200A MIR183
18 rectum cancer 30.1 MIR31 MIR21 MIR200A
19 ovarian disease 30.1 MIR27A MIR22 MIR21 MIR200B MIR200A MIR140
20 lymphoma, non-hodgkin, familial 30.0 MIR34A MIR31 MIR27A MIR21 MIR200B MIR140
21 gastric cancer 30.0 MIR34A MIR31 MIR29C MIR27B MIR27A MIR22
22 kidney cancer 30.0 MIR378A MIR29C MIR27A MIR21 MIR200B MIR122
23 bladder cancer 29.9 MIR34A MIR31 MIR29C MIR21 MIR200A MIR10B
24 colorectal cancer 29.9 MIR34A MIR31 MIR29C MIR27B MIR27A MIR26A1
25 prostate disease 29.9 MIR34A MIR31 MIR27A MIR22 MIR21 MIR200B
26 esophageal cancer 29.7 MIR34A MIR31 MIR27A MIR21 MIR200A MIR183
27 prostate cancer 29.7 MSR1 MIR34A MIR31 MIR27B MIR27A MIR22
28 lung cancer susceptibility 3 29.6 MIR31 MIR29C MIR27A MIR21 MIR200B MIR200A
29 pancreas disease 29.5 MIR34A MIR33A MIR31 MIR27B MIR27A MIR22
30 breast cancer 29.4 MSR1 MIR34A MIR31 MIR29C MIR27A MIR22
31 lung cancer 29.3 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27B
32 ovarian cancer 29.2 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
33 gastrointestinal system disease 28.9 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27B
34 fatty liver disease, nonalcoholic 2 12.6
35 fatty liver disease, nonalcoholic 1 12.5
36 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.4
37 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.2
38 hypertriglyceridemia, transient infantile 12.1
39 lipodystrophy, familial partial, type 2 11.9
40 liver disease 11.8
41 fatty liver disease 11.8
42 reye syndrome 11.7
43 congenital generalized lipodystrophy 11.4
44 familial partial lipodystrophy 11.4
45 mitochondrial dna depletion syndrome 4a 11.4
46 adrenomyodystrophy 11.4
47 visceral steatosis, congenital 11.4
48 corticosteroid-binding globulin deficiency 11.2
49 lipodystrophy, congenital generalized, type 2 11.2
50 3-methylglutaconic aciduria, type v 11.2
51 lipodystrophy, congenital generalized, type 3 11.2
52 interstitial lung and liver disease 11.2
53 lipodystrophy, familial partial, type 6 11.2
54 fibrosis, neurodegeneration, and cerebral angiomatosis 11.2
55 hyperlipidemia, familial combined, 2 11.1
56 neutral lipid storage disease with myopathy 11.1
57 aromatase deficiency 11.1
58 combined oxidative phosphorylation deficiency 16 11.1
59 morbid obesity and spermatogenic failure 11.1
60 chylomicron retention disease 11.1
61 pearson marrow-pancreas syndrome 11.1
62 lipodystrophy, congenital generalized, type 1 11.1
63 hypermanganesemia with dystonia 1 11.1
64 lipodystrophy, congenital generalized, type 4 11.1
65 lipodystrophy, familial partial, type 5 11.1
66 combined oxidative phosphorylation deficiency 21 11.1
67 infantile liver failure syndrome 2 11.1
68 mitochondrial dna depletion syndrome 15 11.1
69 bile acid synthesis defect, congenital, 6 11.1
70 microcephaly, developmental delay, and brittle hair syndrome 11.1
71 liver cirrhosis 11.0
72 hypertriglyceridemia, familial 10.9
73 fibrosis of extraocular muscles, congenital, 1 10.9
74 body mass index quantitative trait locus 1 10.9
75 viral hepatitis 10.9
76 chronic kidney disease 10.8
77 hyperinsulinism 10.8
78 leptin deficiency or dysfunction 10.8
79 atherosclerosis susceptibility 10.8
80 glucose intolerance 10.8
81 polycystic ovary syndrome 10.8
82 hyperglycemia 10.8
83 hypercholesterolemia, familial, 1 10.8
84 hypothyroidism 10.7
85 hyperuricemia 10.7
86 cryptogenic cirrhosis 10.7
87 kidney disease 10.7
88 rickets 10.7
89 alcohol use disorder 10.7
90 diabetes mellitus 10.7
91 diabetes mellitus, noninsulin-dependent 10.7
92 sleep apnea 10.7
93 overgrowth syndrome 10.7
94 hemosiderosis 10.6
95 rare hereditary hemochromatosis 10.6
96 ischemic bone disease 10.6 MIR22 MIR21 MIR122
97 pustulosis of palm and sole 10.6
98 miyoshi muscular dystrophy 1 10.6 MIR34A MIR21 MIR132
99 coronary heart disease 1 10.6
100 dermatomyositis 10.6 MIR34A MIR21 MIR132
101 hyperlipoproteinemia, type iii 10.6
102 lipoprotein quantitative trait locus 10.6
103 inflammatory bowel disease 10.6
104 hepatitis c 10.6
105 polymyositis 10.6 MIR21 MIR132
106 body mass index quantitative trait locus 9 10.6
107 body mass index quantitative trait locus 8 10.6
108 body mass index quantitative trait locus 4 10.6
109 body mass index quantitative trait locus 10 10.6
110 body mass index quantitative trait locus 7 10.6
111 body mass index quantitative trait locus 12 10.6
112 body mass index quantitative trait locus 14 10.6
113 body mass index quantitative trait locus 18 10.6
114 body mass index quantitative trait locus 19 10.6
115 body mass index quantitative trait locus 20 10.6
116 hyperandrogenism 10.6
117 hepatitis b 10.6
118 bone inflammation disease 10.6 MIR34A MIR21 MIR140
119 glioma 10.5 MIR34A MIR21 MIR140 MIR10B
120 portal hypertension 10.5
121 gestational diabetes 10.5
122 autoimmune hepatitis 10.5
123 leiomyoma, uterine 10.5 MIR34A MIR29C MIR27A MIR21
124 atrial fibrillation 10.5
125 vascular disease 10.5
126 nemaline myopathy 10.5 MIR34A MIR29C MIR132
127 disease of mental health 10.5 MIR22 MIR21 MIR140 MIR132 MIR122
128 leukocyte disease 10.5 MIR27A MIR21 MIR200B MIR140
129 autosomal genetic disease 10.5 MIR27A MIR22 MIR21 MIR140
130 bone marrow cancer 10.5 MIR34A MIR27A MIR26A1 MIR21 MIR140
131 tongue disease 10.5 MIR33A MIR31 MIR21
132 laryngeal disease 10.5 MIR34A MIR31 MIR21 MIR183
133 chromosomal disease 10.5 MIR22 MIR21 MIR183 MIR140
134 autonomic nervous system neoplasm 10.5 MIR34A MIR27A MIR21
135 hemochromatosis, type 1 10.5
136 bone mineral density quantitative trait locus 3 10.5
137 primary biliary cirrhosis 10.5
138 ovary epithelial cancer 10.5 MIR21 MIR200A MIR183
139 peripheral nervous system neoplasm 10.5 MIR34A MIR27A MIR21
140 malignant ovarian surface epithelial-stromal neoplasm 10.5 MIR21 MIR200A MIR183
141 prion disease 10.5 MIR22 MIR200B MIR132
142 floating-harbor syndrome 10.4
143 mouth disease 10.4 MIR31 MIR21 MIR200B MIR140
144 hypertension, essential 10.4
145 helicobacter pylori infection 10.4
146 periodontitis 10.4
147 bile duct disease 10.4 MIR378A MIR200A MIR140
148 disseminated intravascular coagulation 10.4
149 oral cavity cancer 10.4 MIR31 MIR27B MIR21 MIR140 MIR10B
150 gastroesophageal reflux 10.4
151 varicose veins 10.4
152 gallbladder disease 1 10.4
153 microvascular complications of diabetes 3 10.4
154 microvascular complications of diabetes 4 10.4
155 microvascular complications of diabetes 5 10.4
156 microvascular complications of diabetes 6 10.4
157 microvascular complications of diabetes 7 10.4
158 hepatic coma 10.4
159 hepatic encephalopathy 10.4
160 autoimmune disease of central nervous system 10.4 MIR27A MIR22 MIR132
161 ovarian serous carcinoma 10.4 MIR27A MIR21 MIR200B MIR200A MIR10B
162 chromosomal deletion syndrome 10.4 MIR22 MIR200B MIR200A MIR183
163 chromophobe renal cell carcinoma 10.4 MIR21 MIR200B MIR183
164 eye disease 10.4 MIR29C MIR27B MIR27A MIR21 MIR140 MIR122
165 proteasome-associated autoinflammatory syndrome 1 10.4
166 hepatitis c virus 10.4
167 heart disease 10.4
168 hepatitis a 10.4
169 cholestasis 10.4
170 arteriosclerosis 10.4
171 heart valve disease 10.4
172 coronary stenosis 10.4
173 adenoma 10.4
174 cytokine deficiency 10.4
175 autonomic dysfunction 10.4
176 hypoxia 10.4
177 rapidly involuting congenital hemangioma 10.4
178 integumentary system disease 10.4 MIR31 MIR21 MIR140
179 hellp syndrome 10.4
180 deafness, autosomal dominant 50 10.4 MIR183 MIR140
181 cell type benign neoplasm 10.3 MIR27B MIR22 MIR21 MIR200A MIR140 MIR132
182 alcohol dependence 10.3
183 autoimmune disease 10.3
184 celiac disease 1 10.3
185 prostatic hyperplasia, benign 10.3
186 homocysteinemia 10.3
187 psoriatic arthritis 10.3
188 cholangiocarcinoma 10.3
189 cholelithiasis 10.3
190 pre-eclampsia 10.3
191 prostatic hypertrophy 10.3
192 esophageal varix 10.3
193 alcoholic hepatitis 10.3
194 gout 10.3
195 diarrhea 10.3
196 eclampsia 10.3
197 hypogonadism 10.3
198 prostatic adenoma 10.3
199 intrahepatic cholangiocarcinoma 10.3
200 hepatoblastoma 10.3
201 cholangitis 10.3
202 central nervous system disease 10.3 MIR34A MIR27A MIR22 MIR21 MIR200B MIR140
203 connective tissue cancer 10.3 MIR34A MIR31 MIR29C MIR27A MIR21 MIR140
204 nasopharyngeal carcinoma 10.3 MIR378A MIR31 MIR29C MIR21 MIR10B
205 bladder disease 10.3 MIR34A MIR31 MIR29C MIR27B MIR21 MIR200A
206 lymphatic system cancer 10.3 MIR34A MIR31 MIR29C MIR27A MIR21 MIR200B
207 lymphatic system disease 10.3 MIR34A MIR31 MIR29C MIR27A MIR21 MIR200B
208 acanthosis nigricans 10.3
209 fructose intolerance, hereditary 10.3
210 wilson disease 10.3
211 cholangitis, primary sclerosing 10.3
212 colorectal adenoma 10.3
213 covid-19 10.3
214 urolithiasis 10.3
215 sclerosing cholangitis 10.3
216 constipation 10.3
217 skin disease 10.3
218 pituitary gland disease 10.3
219 sleep disorder 10.3
220 end stage renal disease 10.3
221 eating disorder 10.3
222 crohn's disease 10.3
223 hypopituitarism 10.3
224 hypoglycemia 10.3
225 pik3ca-related overgrowth syndrome 10.3
226 familial hypercholesterolemia 10.3
227 pancreatitis 10.2
228 nasopharyngeal disease 10.2 MIR31 MIR29C MIR27A MIR21 MIR140 MIR132
229 pharynx cancer 10.2 MIR31 MIR29C MIR27A MIR21 MIR140 MIR132
230 upper respiratory tract disease 10.2 MIR31 MIR29C MIR27A MIR21 MIR140 MIR132
231 spinal disease 10.2 MIR27A MIR21 MIR140
232 esophageal disease 10.2 MIR34A MIR31 MIR21 MIR200B MIR200A MIR183
233 apnea, obstructive sleep 10.2
234 blood group--newfoundland 10.2
235 cardiac conduction defect 10.2
236 hair whorl 10.2
237 prader-willi syndrome 10.2
238 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
239 insulin-like growth factor i 10.2
240 lysosomal acid lipase deficiency 10.2
241 pulmonary disease, chronic obstructive 10.2
242 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
243 alpha-1-antitrypsin deficiency 10.2
244 leukemia, acute lymphoblastic 3 10.2
245 peripheral vascular disease 10.2
246 exanthem 10.2
247 sexual disorder 10.2
248 siderosis 10.2
249 cholecystolithiasis 10.2
250 portal vein thrombosis 10.2
251 low compliance bladder 10.2
252 carotid stenosis 10.2
253 amenorrhea 10.2
254 cholesterol ester storage disease 10.2
255 thrombocytopenia 10.2
256 hepatitis 10.2
257 retinal vascular disease 10.2
258 bilirubin metabolic disorder 10.2
259 glycogen storage disease 10.2
260 ischemia 10.2
261 mood disorder 10.2
262 peripheral nervous system disease 10.2
263 nephrolithiasis 10.2
264 congestive heart failure 10.2
265 b-cell lymphoma 10.2
266 peptic ulcer disease 10.2
267 placenta disease 10.2
268 hyperthyroidism 10.2
269 peritonitis 10.2
270 lung disease 10.2
271 neuropathy 10.2
272 acute myocardial infarction 10.2
273 growth hormone deficiency 10.2
274 splenomegaly 10.2
275 syncope 10.2
276 cerebrofacial arteriovenous metameric syndrome 10.2
277 acute liver failure 10.2
278 digeorge syndrome 10.2 MIR31 MIR22 MIR200B MIR200A MIR183 MIR132
279 oral squamous cell carcinoma 10.2 MIR34A MIR31 MIR27B MIR27A MIR21 MIR200B
280 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
281 deficiency anemia 10.2
282 autosomal recessive disease 10.2
283 estrogen-receptor positive breast cancer 10.2
284 hemolytic anemia 10.2
285 myotonic dystrophy 10.2
286 leukemia, acute myeloid 10.2 MIR378A MIR34A MIR31 MIR27B MIR27A MIR22
287 melanoma 10.2 MIR34A MIR31 MIR27A MIR200B MIR200A MIR183
288 kwashiorkor 10.2
289 graves' disease 10.2
290 cervical cancer 10.1 MIR34A MIR31 MIR21 MIR200B MIR200A MIR183
291 biotin deficiency 10.1
292 hemangioma 10.1
293 breast disease 10.1 MIR34A MIR31 MIR27A MIR22 MIR21 MIR200B
294 urinary system disease 10.1 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
295 connective tissue disease 10.1 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
296 carnitine deficiency, systemic primary 10.1
297 severe pre-eclampsia 10.0
298 alzheimer disease 10.0
299 spondyloarthropathy 1 10.0
300 progressive familial heart block, type ia 10.0
301 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.0
302 hyperlipidemia, familial combined, 3 10.0
303 hypogonadotropic hypogonadism 7 with or without anosmia 10.0
304 migraine with or without aura 1 10.0
305 optic atrophy 1 10.0
306 osteoporosis 10.0
307 pancreatitis, hereditary 10.0
308 abetalipoproteinemia 10.0
309 alstrom syndrome 10.0
310 ataxia-telangiectasia 10.0
311 citrullinemia, classic 10.0
312 cystic fibrosis 10.0
313 hypogonadism, male 10.0
314 immune deficiency disease 10.0
315 familial mediterranean fever 10.0
316 pituitary hormone deficiency, combined, 2 10.0
317 scott syndrome 10.0
318 chanarin-dorfman syndrome 10.0
319 retinitis pigmentosa 11 10.0
320 stroke, ischemic 10.0
321 convulsions, familial infantile, with paroxysmal choreoathetosis 10.0
322 hemochromatosis, type 2a 10.0
323 macular degeneration, age-related, 1 10.0
324 citrullinemia, type ii, adult-onset 10.0
325 progressive familial heart block, type ib 10.0
326 abdominal obesity-metabolic syndrome 1 10.0
327 maturity-onset diabetes of the young 10.0
328 anorexia nervosa 10.0
329 niemann-pick disease, type c2 10.0
330 myocardial infarction 10.0
331 carotid intimal medial thickness 2 10.0
332 major depressive disorder 10.0
333 bone mineral density quantitative trait locus 8 10.0
334 adiponectin, serum level of, quantitative trait locus 1 10.0
335 bone mineral density quantitative trait locus 15 10.0
336 ectodermal dysplasia-syndactyly syndrome 2 10.0
337 beta-thalassemia 10.0
338 barrett esophagus 10.0
339 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.0
340 hypobetalipoproteinemia, familial, 1 10.0
341 carbonic anhydrase va deficiency, hyperammonemia due to 10.0
342 autoimmune lymphoproliferative syndrome, type v 10.0
343 fetal akinesia deformation sequence 2 10.0
344 angina pectoris 10.0
345 hyperphosphatemia 10.0
346 serine deficiency 10.0
347 metabolic acidosis 10.0
348 peripheral artery disease 10.0
349 colitis 10.0
350 thrombosis 10.0
351 hypogonadotropic hypogonadism 10.0
352 hemochromatosis type 2 10.0
353 aortic atherosclerosis 10.0
354 thalassemia 10.0
355 left bundle branch hemiblock 10.0
356 bacterial infectious disease 10.0
357 nasopharyngitis 10.0
358 osteomalacia 10.0
359 brucellosis 10.0
360 keratomalacia 10.0
361 familial hyperlipidemia 10.0
362 hepatorenal syndrome 10.0
363 esophagitis 10.0
364 inflammatory spondylopathy 10.0
365 pancytopenia 10.0
366 secondary hyperparathyroidism 10.0
367 telangiectasis 10.0
368 acute cystitis 10.0
369 right bundle branch block 10.0
370 porphyria 10.0
371 exocrine pancreatic insufficiency 10.0
372 hyperparathyroidism 10.0
373 peptic esophagitis 10.0
374 alcoholic liver cirrhosis 10.0
375 gonadal dysgenesis 10.0
376 mental depression 10.0
377 neuroendocrine tumor 10.0
378 mitral valve stenosis 10.0
379 islet cell tumor 10.0
380 post-traumatic stress disorder 10.0
381 dental caries 10.0
382 transient cerebral ischemia 10.0
383 hidradenitis suppurativa 10.0
384 hidradenitis 10.0
385 motor neuron disease 10.0
386 psychotic disorder 10.0
387 acute pancreatitis 10.0
388 plague 10.0
389 turner syndrome 10.0
390 lactic acidosis 10.0
391 craniopharyngioma 10.0
392 insulinoma 10.0
393 gastritis 10.0
394 thyroid gland disease 10.0
395 pneumonia 10.0
396 acute stress disorder 10.0
397 bronchitis 10.0
398 spondylitis 10.0
399 cerebrovascular disease 10.0
400 muscular atrophy 10.0
401 myocarditis 10.0
402 choline deficiency disease 10.0
403 herpes simplex 10.0
404 ulcerative colitis 10.0
405 viral infectious disease 10.0
406 diabetes insipidus 10.0
407 noma 10.0
408 biliary tract disease 10.0
409 diabetic neuropathy 10.0
410 irritable bowel syndrome 10.0
411 isolated gonadotropin-releasing hormone deficiency 10.0
412 48,xyyy 10.0
413 familial hypertension 10.0
414 pituitary stalk interruption syndrome 10.0
415 pure autonomic failure 10.0
416 depression 10.0
417 headache 10.0
418 spinal cord injury 10.0
419 acute sensory ataxic neuropathy 10.0
420 extracranial carotid artery aneurysm 10.0
421 genetic obesity 10.0
422 neurometabolic disorder due to serine deficiency 10.0
423 antipyrine metabolism 10.0
424 systemic lupus erythematosus 10.0
425 nasopalpebral lipoma-coloboma syndrome 10.0
426 porphyria cutanea tarda 10.0
427 variegate porphyria 10.0
428 pulmonary fibrosis, idiopathic 10.0
429 schistosoma mansoni infection, susceptibility/ 10.0
430 thrombophilia due to thrombin defect 10.0
431 anemia, autoimmune hemolytic 10.0
432 myeloma, multiple 10.0
433 myeloperoxidase deficiency 10.0
434 netherton syndrome 10.0
435 shwachman-diamond syndrome 1 10.0
436 werner syndrome 10.0
437 tubulin, beta 10.0
438 leukemia, acute lymphoblastic 10.0
439 autoimmune pancreatitis 10.0
440 hepatocellular adenoma 10.0
441 infective endocarditis 10.0
442 lymphoma 10.0
443 lymphoproliferative syndrome 10.0
444 bone resorption disease 10.0
445 lymphoblastic lymphoma 10.0
446 mucositis 10.0
447 chronic neutrophilic leukemia 10.0
448 endocarditis 10.0
449 chronic pyelonephritis 10.0
450 respiratory failure 10.0
451 pyelonephritis 10.0
452 leukemia 10.0
453 schistosomiasis 10.0
454 nodular nonsuppurative panniculitis 10.0
455 panniculitis 10.0
456 drug-induced hepatitis 10.0
457 myeloproliferative neoplasm 10.0
458 tic disorder 10.0
459 acute kidney failure 10.0
460 lipomatosis 10.0
461 teratoma 10.0
462 pulmonary fibrosis 10.0
463 pituitary adenoma 10.0
464 hepatocellular clear cell carcinoma 10.0
465 nutritional deficiency disease 10.0
466 cowden syndrome 10.0
467 neuroblastoma 10.0
468 appendicitis 10.0
469 arthritis 10.0
470 lupus erythematosus 10.0
471 lichen planus 10.0
472 chronic cholangitis 10.0
473 pulmonary embolism 10.0
474 smoldering myeloma 10.0
475 lipogranulomatosis 10.0
476 oral lichen planus 10.0
477 tremor 10.0
478 posttransplant acute limbic encephalitis 10.0
479 systemic autoimmune disease 10.0
480 endotheliitis 10.0
481 male reproductive system disease 10.0 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
482 intrahepatic cholestasis of pregnancy 10.0
483 nephrotic syndrome 10.0
484 muscular dystrophy 10.0
485 male reproductive organ cancer 10.0 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
486 pernicious anemia 10.0
487 renal glucosuria 10.0
488 3-methylglutaconic aciduria, type iii 10.0
489 accelerated tumor formation 10.0
490 infantile liver failure syndrome 1 10.0
491 lung disease, immunodeficiency, and chromosome breakage syndrome 10.0
492 hypertrophic scars 10.0
493 chlamydia pneumonia 10.0
494 autoimmune gastritis 10.0
495 diffuse large b-cell lymphoma 10.0
496 secondary progressive multiple sclerosis 10.0
497 crohn's colitis 10.0
498 borderline personality disorder 10.0
499 chlamydia 10.0
500 generalized anxiety disorder 10.0
501 personality disorder 10.0
502 ectodermal dysplasia 10.0
503 ascending colon cancer 10.0
504 germinoma 10.0
505 anovulation 10.0
506 systemic scleroderma 10.0
507 mature teratoma 10.0
508 berardinelli-seip congenital lipodystrophy 10.0
509 pituitary tumors 10.0
510 syndromic obesity 10.0
511 refractory celiac disease 10.0
512 liver adenomatosis 10.0
513 serotonin syndrome 10.0
514 renal cell carcinoma, nonpapillary 10.0 MIR34A MIR31 MIR29C MIR27A MIR26A1 MIR22
515 cervix disease 10.0 MIR34A MIR31 MIR29C MIR22 MIR21 MIR200B
516 hematologic cancer 10.0 MIR34A MIR33A MIR31 MIR29C MIR27A MIR22
517 dentinogenesis imperfecta type 2 10.0
518 aging 10.0
519 pancreatic adenocarcinoma 10.0
520 intermediate coronary syndrome 10.0
521 methemoglobinemia 10.0
522 rheumatoid arthritis 10.0
523 dermatitis, atopic 10.0
524 endometritis 10.0
525 cholecystitis 10.0
526 dermatitis 10.0
527 myopathy 10.0
528 hypothalamic obesity 10.0
529 helix syndrome 10.0
530 endocrine system disease 9.9 MIR33A MIR31 MIR27B MIR27A MIR22 MIR21
531 uterine anomalies 9.9 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
532 immune system disease 9.9 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
533 squamous cell carcinoma, head and neck 9.9 MIR33A MIR31 MIR29C MIR27A MIR22 MIR21
534 thoracic cancer 9.9 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
535 atrial standstill 1 9.9
536 triiodothyronine receptor auxiliary protein 9.9
537 ataxia and polyneuropathy, adult-onset 9.9
538 mitochondrial trifunctional protein deficiency 9.9
539 mastitis 9.9
540 prediabetes syndrome 9.9
541 allergic hypersensitivity disease 9.9
542 impotence 9.9
543 gastroenteritis 9.9
544 thrombophilia 9.9
545 severe acute respiratory syndrome 9.9
546 hepatitis e 9.9
547 infertility 9.9
548 respiratory system disease 9.9 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
549 respiratory system cancer 9.9 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
550 cholestasis, intrahepatic, of pregnancy, 1 9.9
551 platelet glycoprotein iv deficiency 9.9
552 arrhythmogenic right ventricular cardiomyopathy 9.9
553 lipoid nephrosis 9.9
554 dilated cardiomyopathy 9.9
555 azoospermia 9.9
556 acromegaly 9.9
557 multiple endocrine neoplasia 9.9
558 sideroblastic anemia 9.9
559 atp8b1 deficiency 9.9
560 mitochondrial disorders 9.9
561 fasting hypoglycemia 9.9
562 metastatic insulinoma 9.9
563 chronic intestinal failure 9.9
564 colonic disease 9.9 MIR378A MIR34A MIR31 MIR29C MIR27B MIR26A1
565 leukemia, chronic lymphocytic 9.9 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27A
566 nephrolithiasis, calcium oxalate 9.8
567 hypertensive heart disease 9.8
568 toxic shock syndrome 9.8
569 iron metabolism disease 9.8
570 human immunodeficiency virus infectious disease 9.8
571 pellagra 9.8
572 neonatal adrenoleukodystrophy 9.8
573 encephalopathy 9.8
574 inflammatory myopathy with abundant macrophages 9.8
575 carpal tunnel syndrome 9.8
576 cryoglobulinemia, familial mixed 9.8
577 huntington disease 9.8
578 neutrophil migration 9.8
579 retinoblastoma 9.8
580 sarcoidosis 1 9.8
581 schizophrenia 9.8
582 enterocolitis 9.8
583 ocular motor apraxia 9.8
584 46,xy sex reversal 11 9.8
585 arts syndrome 9.8
586 citrullinemia, type ii, neonatal-onset 9.8
587 variola major 9.8
588 thrombotic thrombocytopenic purpura 9.8
589 paranoid schizophrenia 9.8
590 cryoglobulinemia 9.8
591 purpura 9.8
592 seminoma 9.8
593 familial retinoblastoma 9.8
594 testis seminoma 9.8
595 axonal neuropathy 9.8
596 smallpox 9.8
597 hepatopulmonary syndrome 9.8
598 amyloidosis 9.8
599 47,xyy 9.8
600 seronegative autoimmune hepatitis 9.8
601 polykaryocytosis inducer 9.8
602 down syndrome 9.8
603 afibrinogenemia, congenital 9.8
604 diabetes mellitus, type i 9.8
605 albinism-deafness syndrome 9.8
606 yemenite deaf-blind hypopigmentation syndrome 9.8
607 huntington disease-like 3 9.8
608 huntington disease-like 2 9.8
609 resting heart rate, variation in 9.8
610 endometrial cancer 9.8
611 hyperprolactinemia 9.8
612 analbuminemia 9.8
613 pain agnosia 9.8
614 gallbladder disease 9.8
615 cardiac arrest 9.8
616 bone disease 9.8
617 gastric ulcer 9.8
618 pulmonary edema 9.8
619 protein-energy malnutrition 9.8
620 obstructive jaundice 9.8
621 polyneuropathy 9.8
622 ichthyosis 9.8
623 thrombocytosis 9.8
624 colon adenocarcinoma 9.8
625 anuria 9.8
626 angiomyolipoma 9.8
627 hypokalemia 9.8
628 cataract 9.8
629 homocystinuria 9.8
630 placental abruption 9.8
631 pyridoxine deficiency 9.8
632 cerebral arteriosclerosis 9.8
633 thyroid carcinoma 9.8
634 female reproductive system disease 9.8 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
635 endocrine gland cancer 9.8 MIR34A MIR33A MIR31 MIR29C MIR27A MIR26A1
636 reproductive system disease 9.8 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
637 cirrhosis, familial 9.7
638 multiple endocrine neoplasia, type i 9.7
639 adermatoglyphia 9.7
640 fucosidase regulator 9.7
641 kaposi sarcoma 9.7
642 papillomatosis, confluent and reticulated 9.7
643 hutchinson-gilford progeria syndrome 9.7
644 acyl-coa dehydrogenase, very long-chain, deficiency of 9.7
645 argininosuccinic aciduria 9.7
646 fanconi anemia, complementation group c 9.7
647 fanconi anemia, complementation group a 9.7
648 homocystinuria due to cystathionine beta-synthase deficiency 9.7
649 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 9.7
650 mandibuloacral dysplasia with type a lipodystrophy 9.7
651 microcephaly 1, primary, autosomal recessive 9.7
652 pancreatic agenesis 1 9.7
653 hyper-igd syndrome 9.7
654 short syndrome 9.7
655 sudden infant death syndrome 9.7
656 thymoma, familial 9.7
657 maturity-onset diabetes of the young, type 3 9.7
658 patent ductus venosus 9.7
659 autoimmune lymphoproliferative syndrome 9.7
660 xanthomatosis 9.7
661 huntington disease-like 1 9.7
662 aceruloplasminemia 9.7
663 late-onset retinal degeneration 9.7
664 glycine n-methyltransferase deficiency 9.7
665 isobutyryl-coa dehydrogenase deficiency 9.7
666 major affective disorder 8 9.7
667 major affective disorder 9 9.7
668 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 9.7
669 complement component 3 deficiency, autosomal recessive 9.7
670 cyanosis, transient neonatal 9.7
671 muscle hypertrophy 9.7
672 myelodysplastic syndrome 9.7
673 glucocorticoid resistance, generalized 9.7
674 angiosarcoma 9.7
675 hemophagocytic lymphohistiocytosis 9.7
676 follicular lymphoma 9.7
677 organic acidemia 9.7
678 scoliosis 9.7
679 progressive familial intrahepatic cholestasis 9.7
680 intestinal pseudo-obstruction 9.7
681 pinta disease 9.7
682 protein-losing enteropathy 9.7
683 renal hypertension 9.7
684 emery-dreifuss muscular dystrophy 9.7
685 hypertrophic cardiomyopathy 9.7
686 marasmus 9.7
687 acute leukemia 9.7
688 alcoholic cardiomyopathy 9.7
689 hypolipoproteinemia 9.7
690 thrombocytopenia due to platelet alloimmunization 9.7
691 papillary carcinoma 9.7
692 thymoma 9.7
693 bipolar disorder 9.7
694 inappropriate adh syndrome 9.7
695 acute myocarditis 9.7
696 microsporidiosis 9.7
697 mitochondrial myopathy 9.7
698 mitochondrial metabolism disease 9.7
699 complement component 3 deficiency 9.7
700 osteoarthritis 9.7
701 retinal degeneration 9.7
702 mitochondrial encephalomyopathy 9.7
703 urea cycle disorder 9.7
704 intracranial hypertension 9.7
705 primary ciliary dyskinesia 9.7
706 miliary tuberculosis 9.7
707 mixed phenotype acute leukemia 9.7
708 acid sphingomyelinase deficiency 9.7
709 insr-related severe syndromic insulin resistance 9.7
710 acute ackee fruit intoxication 9.7
711 chromosomal triplication 9.7
712 fetal macrosomia 9.7
713 secondary adrenal insufficiency 9.7
714 aldosterone-producing adenoma 9.7
715 spinocerebellar degeneration 9.7
716 primary hemophagocytic lymphohistiocytosis 9.7
717 familial intrahepatic cholestasis 9.7
718 paracetamol poisoning 9.7
719 argyria 9.7
720 obesity due to melanocortin 4 receptor deficiency 9.7
721 other metabolic disease 9.7
722 nervous system disease 9.7 MIR34A MIR31 MIR29C MIR27B MIR27A MIR22
723 aortic aneurysm, familial abdominal, 1 9.7
724 neurofibromatosis, type ii 9.7
725 cardiac arrhythmia 9.7
726 hashimoto thyroiditis 9.7
727 hernia, hiatus 9.7
728 gilbert syndrome 9.7
729 lipomatosis, multiple 9.7
730 myositis 9.7
731 pheochromocytoma 9.7
732 small cell cancer of the lung 9.7
733 thoracolaryngopelvic dysplasia 9.7
734 thrombocytopenic purpura, autoimmune 9.7
735 acyl-coa dehydrogenase, medium-chain, deficiency of 9.7
736 acyl-coa dehydrogenase, short-chain, deficiency of 9.7
737 adrenocortical carcinoma, hereditary 9.7
738 bardet-biedl syndrome 1 9.7
739 coloboma, ocular, autosomal recessive 9.7
740 crigler-najjar syndrome, type i 9.7
741 3-hydroxyacyl-coa dehydrogenase deficiency 9.7
742 multiple acyl-coa dehydrogenase deficiency 9.7
743 hemihyperplasia, isolated 9.7
744 hypervitaminosis a 9.7
745 orotic aciduria 9.7
746 laron syndrome 9.7
747 asplenia, isolated congenital 9.7
748 dihydropyrimidine dehydrogenase deficiency 9.7
749 muscular dystrophy, becker type 9.7
750 menkes disease 9.7
751 pituitary adenoma, prolactin-secreting 9.7
752 budd-chiari syndrome 9.7
753 chudley-mccullough syndrome 9.7
754 langerhans cell histiocytosis 9.7
755 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.7
756 alveolar soft part sarcoma 9.7
757 allergic rhinitis 9.7
758 lissencephaly 1 9.7
759 anxiety 9.7
760 human immunodeficiency virus type 1 9.7
761 malaria 9.7
762 legius syndrome 9.7
763 congenital disorder of glycosylation, type in 9.7
764 diabetes mellitus, ketosis-prone 9.7
765 muscular dystrophy, congenital, lmna-related 9.7
766 hepatic lipase deficiency 9.7
767 coronary heart disease 6 9.7
768 peripartum cardiomyopathy 9.7
769 muscular dystrophy, limb-girdle, autosomal recessive 18 9.7
770 alacrima, achalasia, and mental retardation syndrome 9.7
771 monocarboxylate transporter 1 deficiency 9.7
772 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
773 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
774 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
775 adrenal cortical carcinoma 9.7
776 congenital hypothyroidism 9.7
777 lissencephaly 9.7
778 seckel syndrome 9.7
779 atrioventricular block 9.7
780 chronic venous insufficiency 9.7
781 colorectal adenocarcinoma 9.7
782 villous adenoma 9.7
783 adrenal gland pheochromocytoma 9.7
784 withdrawal disorder 9.7
785 microscopic colitis 9.7
786 salmonellosis 9.7
787 acquired generalized lipodystrophy 9.7
788 endometrial hyperplasia 9.7
789 desmoid tumor 9.7
790 venous insufficiency 9.7
791 osteonecrosis 9.7
792 pleomorphic lipoma 9.7
793 leukodystrophy 9.7
794 short bowel syndrome 9.7
795 premature menopause 9.7
796 placenta praevia 9.7
797 pertussis 9.7
798 hypoparathyroidism 9.7
799 vitamin k deficiency bleeding 9.7
800 adult respiratory distress syndrome 9.7
801 hemopericardium 9.7
802 mitral valve insufficiency 9.7
803 iron deficiency anemia 9.7
804 pericardial effusion 9.7
805 cortical blindness 9.7
806 visual epilepsy 9.7
807 conn's syndrome 9.7
808 pulmonary alveolar proteinosis 9.7
809 male infertility 9.7
810 bronchopneumonia 9.7
811 acute kidney tubular necrosis 9.7
812 cardiovascular system disease 9.7
813 renal osteodystrophy 9.7
814 biliary atresia 9.7
815 beriberi 9.7
816 opisthorchiasis 9.7
817 hereditary angioedema 9.7
818 angioedema 9.7
819 duodenal ulcer 9.7
820 squamous cell carcinoma 9.7
821 cardiovascular cancer 9.7
822 status epilepticus 9.7
823 gaucher's disease 9.7
824 enthesopathy 9.7
825 hemorrhagic disease 9.7
826 granulomatous hepatitis 9.7
827 generalized atherosclerosis 9.7
828 basal cell carcinoma 9.7
829 cystadenoma 9.7
830 hemangioma of liver 9.7
831 adenocarcinoma 9.7
832 aspiration pneumonitis 9.7
833 lipid pneumonia 9.7
834 hepatic angiomyolipoma 9.7
835 histiocytosis 9.7
836 carotid artery disease 9.7
837 pancreatic ductal adenocarcinoma 9.7
838 aortic aneurysm 9.7
839 arthropathy 9.7
840 thrombophlebitis 9.7
841 adrenal cortical adenocarcinoma 9.7
842 syphilis 9.7
843 carcinosarcoma 9.7
844 rhinitis 9.7
845 bile duct cancer 9.7
846 holoprosencephaly 9.7
847 brain edema 9.7
848 movement disease 9.7
849 acute pyelonephritis 9.7
850 ovarian serous cystadenocarcinoma 9.7
851 severe combined immunodeficiency 9.7
852 acquired immunodeficiency syndrome 9.7
853 adrenal adenoma 9.7
854 thyroiditis 9.7
855 ileus 9.7
856 influenza 9.7
857 herpes zoster 9.7
858 duodenitis 9.7
859 subacute delirium 9.7
860 vasculitis 9.7
861 narcolepsy 9.7
862 tyrosinemia 9.7
863 pulmonary emphysema 9.7
864 hemorrhoid 9.7
865 alopecia 9.7
866 hypoalphalipoproteinemia 9.7
867 limb-girdle muscular dystrophy 9.7
868 muscular dystrophy, duchenne and becker type 9.7
869 congenital disorders of n-linked glycosylation and multiple pathway 9.7
870 medium-chain acyl-coenzyme a dehydrogenase deficiency 9.7
871 phosphorylase kinase deficiency 9.7
872 fibromatosis 9.7
873 glucagonoma 9.7
874 lymphosarcoma 9.7
875 mallory-weiss syndrome 9.7
876 rohhad 9.7
877 visceral steatosis 9.7
878 anoxia 9.7
879 dysphagia 9.7
880 seizure disorder 9.7
881 acyl-coa dehydrogenase deficiency 9.7
882 premature aging 9.7
883 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.7
884 polyploidy 9.7
885 genetic lipodystrophy 9.7
886 rare inflammatory bowel disease 9.7
887 precursor t-cell acute lymphoblastic leukemia 9.7
888 gastrointestinal system cancer 9.6 MIR34A MIR33A MIR31 MIR29C MIR27B MIR27A
889 large intestine cancer 9.5 MIR378A MIR34A MIR31 MIR29C MIR27B MIR27A

Graphical network of the top 20 diseases related to Non-Alcoholic Fatty Liver Disease:



Diseases related to Non-Alcoholic Fatty Liver Disease

Symptoms & Phenotypes for Non-Alcoholic Fatty Liver Disease

Drugs & Therapeutics for Non-Alcoholic Fatty Liver Disease

Drugs for Non-Alcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 473, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Losartan Approved Phase 4 114798-26-4 3961
2
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
5
Insulin glulisine Approved Phase 4 207748-29-6
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Glucagon Approved Phase 4 16941-32-5
8
Insulin aspart Approved Phase 4 116094-23-6 16132418
9
Insulin detemir Approved Phase 4 169148-63-4 5311023
10
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
13
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
14
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
18
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
19
Tamoxifen Approved Phase 4 10540-29-1 2733526
20
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
21
Ergotamine Approved Phase 4 113-15-5 8223
22
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
23
Nortriptyline Approved Phase 4 72-69-5 4543
24
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
25
Zidovudine Approved Phase 4 30516-87-1 35370
26
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
27
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Glimepiride Approved Phase 4 93479-97-1 3476
30
Aminolevulinic acid Approved Phase 4 106-60-5 137
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
tannic acid Approved Phase 4 1401-55-4
34
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
35
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
36
Lenvatinib Approved, Investigational Phase 4 417716-92-8
37
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
38
Methyltestosterone Approved Phase 4 58-18-4 6010
39
Testosterone enanthate Approved Phase 4 315-37-7 9416
40
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
41
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
42
Empagliflozin Approved Phase 4 864070-44-0
43
Dulaglutide Approved, Investigational Phase 4 923950-08-7
44
Alogliptin Approved Phase 4 850649-61-5 11450633
45
Metformin Approved Phase 4 657-24-9 14219 4091
46
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
47
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
48
Zinc Approved, Investigational Phase 4 7440-66-6 32051
49
Insulin glargine Approved Phase 4 160337-95-1
50
Saxagliptin Approved Phase 4 361442-04-8 11243969
51
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
52
Ribavirin Approved Phase 4 36791-04-5 37542
53
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
54
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
55
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
56
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735